Clinical Trials Logo

Renal Impairment clinical trials

View clinical trials related to Renal Impairment.

Filter by:

NCT ID: NCT02508506 Completed - Renal Impairment Clinical Trials

Pharmacokinetics and Safety of ALKS 5461 in Subjects With Renal Impairment and Normal Renal Function

Start date: July 2015
Phase: Phase 1
Study type: Interventional

This study will evaluate the effect of various degrees of renal function on the pharmacokinetics and safety of ALKS 5461.

NCT ID: NCT02442258 Completed - Renal Impairment Clinical Trials

Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and Impaired Renal Function

Start date: March 2015
Phase: Phase 1
Study type: Interventional

This is an open-label, single dose study designed to assess the pharmacokinetics and safety of ABT-493 and ABT-530 in subjects with either normal renal function or impaired renal function.

NCT ID: NCT02410642 Completed - Renal Impairment Clinical Trials

NAG-excretion During Cardiopulmonary Bypass

CPBNAG
Start date: November 2011
Phase: N/A
Study type: Observational

NAG is a protein excreted in urine in cases of tubular damage, and is considered a biomarker of kidney injury. Elevated urinary NAG is seen after cardiac surgery, but the clinical significance, pattern of excretion and links to perioperative factors are poorly described. We plan a study of the pattern of NAG-excretion during cardiac surgery with cardiopulmonary bypass, and explore possible associated variables.

NCT ID: NCT02405195 Completed - Renal Impairment Clinical Trials

Renal Perfusion, Filtration and Oxygenation During Cardiopulmonary Bypass (CPB)

ECCSTUD
Start date: October 2011
Phase:
Study type: Observational

Acute kidney injury is a common complication after cardiac surgery with cardiopulmonary bypass (CPB). This study aims to investigate the effects of CPB on renal perfusion, filtration and oxygenation.

NCT ID: NCT02399202 Completed - Renal Impairment Clinical Trials

A Phase I Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Renal Function

Start date: November 6, 2015
Phase: Phase 1
Study type: Interventional

To characterize the pharmacokinetics of LCI699 following a single oral dose in adult subjects with various degrees of impaired renal function.

NCT ID: NCT02397395 Withdrawn - Clinical trials for End-stage Renal Disease

An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis.

Start date: May 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the percentage of participants with sustained virologic response 12 weeks after the actual end of study treatment (SVR12)

NCT ID: NCT02367872 Completed - Hepatic Impairment Clinical Trials

Phase I Open-label Study to Evaluate Pharmacokinetics of TAK-272 in Participants With Renal or Hepatic Impairment

Start date: March 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to examine the effects of renal and hepatic impairment on TAK-272 pharmacokinetics with a single oral administration of TAK-272 in participants with renal or hepatic impairment.

NCT ID: NCT02341599 Completed - Healthy Volunteers Clinical Trials

Study of Pharmacokinetics of a Single IV Dose of CB-238,618 in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Subjects (MK-6183-001)

Start date: December 11, 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to characterize the effect of renal function on the plasma, urine, and dialysate pharmacokinetic profile of MK-6183 (CB-238,618) in humans. The study will also assess the safety profile and tolerability of MK-6183 in healthy participants, participants with varying degrees of renal impairment (RI), or participants with end-stage renal disease (ESRD) requiring hemodialysis (HD), based on estimated glomerular filtration rate (eGFR).

NCT ID: NCT02286622 Completed - Renal Impairment Clinical Trials

A Single Dose Evaluation of the Effects of Renal Impairment on Deflazacort Pharmacokinetics

Start date: December 2014
Phase: Phase 1
Study type: Interventional

This is a non-randomized, open-label, single-dose study to compare the PK of 21 desacetyl-DFZ and, if data permits, deflazacort in 8 subjects with ESRD to that of 8 healthy matched control subjects (age, body mass index [BMI], and gender).

NCT ID: NCT02244762 Completed - Renal Impairment Clinical Trials

Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Extended-Release (HC-ER) in Subjects With Renal Impairment

Start date: February 2011
Phase: Phase 1
Study type: Interventional

Determine the influence of renal impairment on the pharmacokinetics and metabolism of Hydrocodone Bitartrate Extended-Release (HC-ER) 20 mg capsules